Form 4: Coya Therapeutics Director Acquires Stock Options
SEC Filing Form 4
Anabella Villalobos, a director of Coya Therapeutics, Inc., acquired stock options to purchase 5,000 shares of common stock on February 25, 2025.
Summary
- Anabella Villalobos, a director of Coya Therapeutics, Inc., filed a Form 4 to report a transaction.
- On February 25, 2025, Villalobos acquired stock options for 5,000 shares of Coya Therapeutics common stock at an exercise price of $5.97 per share.
- The options vest 100% on the first anniversary of the grant date, subject to continuous service, and expire on February 25, 2035.
- Following the transaction, Villalobos directly owns options for 5,000 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/25/2025 | Date of transaction: Director acquired stock options. |
| 02/25/2025 | Vesting date: 100% of the options will vest on the first anniversary of the date of grant. |
| 02/25/2035 | Expiration date: Stock options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.